Whitehawk Therapeutics Q2 net loss narrows to $16.6M; cash $190M, runway into 2H 2028

Whitehawk Therapeutics, Inc.

Net loss of $16.6M for Q2 2026, compared to $52.6M in Q2 2025; R&D expenses fell to $12.9M from $48.8M.
Cash, equivalents and short-term investments $190.0M at June 30, 2026, up from $145.7M at Dec 31, 2025.
Completed $87.5M private placement equity financing in May 2026 with existing and new investors.
Phase 1 trials for HWK-007 and HWK-016 continue enrolling; initial results expected in 1H 2027.
Entered option agreement with Hangzhou DAC for CPT113 linker-payload and collaboration with Biocytogen for bispecific ADCs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.